Ignite Creation Date:
2025-12-24 @ 12:42 PM
Ignite Modification Date:
2026-01-04 @ 8:45 AM
Study NCT ID:
NCT03294161
Status:
COMPLETED
Last Update Posted:
2017-09-26
First Post:
2017-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007896', 'term': 'Leishmaniasis'}, {'id': 'D016773', 'term': 'Leishmaniasis, Cutaneous'}, {'id': 'D007897', 'term': 'Leishmaniasis, Mucocutaneous'}], 'ancestors': [{'id': 'D056986', 'term': 'Euglenozoa Infections'}, {'id': 'D011528', 'term': 'Protozoan Infections'}, {'id': 'D010272', 'term': 'Parasitic Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D012876', 'term': 'Skin Diseases, Parasitic'}, {'id': 'D000079426', 'term': 'Vector Borne Diseases'}, {'id': 'D012874', 'term': 'Skin Diseases, Infectious'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077485', 'term': 'Meglumine Antimoniate'}], 'ancestors': [{'id': 'D008536', 'term': 'Meglumine'}, {'id': 'D013012', 'term': 'Sorbitol'}, {'id': 'D013402', 'term': 'Sugar Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D006595', 'term': 'Hexosamines'}, {'id': 'D000606', 'term': 'Amino Sugars'}, {'id': 'D002241', 'term': 'Carbohydrates'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 50}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-09', 'completionDateStruct': {'date': '2017-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-09-25', 'studyFirstSubmitDate': '2017-09-22', 'studyFirstSubmitQcDate': '2017-09-25', 'lastUpdatePostDateStruct': {'date': '2017-09-26', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-09-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cure rate or complete cicatrization of the ulcer.', 'timeFrame': '6 months after treatment', 'description': "Bidirectional measurements of ulcers will be taken of the patients' lesions at the initial visit, and at each follow-up visit with standardized caliper. The area involved will be calculated as the product of the two measurements.\n\nAll lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients."}], 'secondaryOutcomes': [{'measure': 'Initial cure rate or complete cicatrization of the ulcer.', 'timeFrame': '2 months after treatment', 'description': "Bidirectional measurements of ulcers will be taken of the patients' lesions at the initial visit, and at each follow-up visit with standardized caliper. The area involved will be calculated as the product of the two measurements.\n\nAll lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients."}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Meglumine antimoniate', 'L.Braziliensis', 'Immunotherapy', 'Immucillin'], 'conditions': ['Leishmaniasis', 'Leishmaniasis, Cutaneous', 'Leishmaniasis; American']}, 'descriptionModule': {'briefSummary': 'A clinical trial to asses efficacy and safety of Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase for topical use associated standard antimonial in the treatment of Cutaneous Leishmaniasis in Bahia, Brazil.', 'detailedDescription': 'The treatment of cutaneous leishmaniasis caused by L. braziliensis in Brazil with pentavalent antimony is associated with a high rate of failure, reaching up to 45% of cases. Additionally, pentavalent antimony is only administered by parenteral route with important toxicity and ulcer lesion healing takes a long time, from 2 to 3 months.\n\nSo, this randomized and controlled clinical trial was designed to compare the efficacy and safety of standard antimonial (20mg/day /kg for 20 days) associated with Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase for topical use versus standard antimonial (20mg/kg/day for 20 days) associated with placebo for topical use in the treatment of Cutaneous Leishmaniasis and Early Cutaneous Leishmaniasis caused by L. braziliensis in the endemic area of Corte de Pedra, Bahia, Brazil.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Newly diagnosed (untreated) cutaneous leishmaniasis or early cutaneous leishmaniasis with localized lesions and a positive culture or diagnosed by polymerase chain reaction (PCR) methods or by intradermal skin testing (Montenegro test).\n* Number of lesions: 1 to 3 ulcerative lesions.\n* Lesion´s diameter: 1 to 5 cm.\n* Disease duration: up to three months.\n\nExclusion Criteria:\n\n* Aspartate aminotransferase, alanine aminotransferase \\>3 times upper limit of normal range\n* Serum creatinine or blood urea nitrogen \\>1.5 times upper limit of normal range\n* Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)\n* Immunodeficiency or antibody to HIV\n* Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant disease, severe malaria, HIV, or other major infectious diseases\n* Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months\n* Negative parasitology (aspirate/biopsy/PCR) or negative Montenegro test\n* Any history of prior anti-leishmania therapy\n* Any condition which compromises ability to comply with the study procedures\n* Lack of ability or willingness to give informed consent (patient and/or parent / legal representative)\n* Anticipated non-availability for study visits/procedure'}, 'identificationModule': {'nctId': 'NCT03294161', 'briefTitle': 'Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis', 'organization': {'class': 'OTHER', 'fullName': 'Hospital Universitário Professor Edgard Santos'}, 'officialTitle': 'Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase as an Adjunct in Cutaneous Leishmaniasis Therapy: a Randomized and Controlled Trial', 'orgStudyIdInfo': {'id': 'Immucillin DI4GTrial'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Immucillin DI4G', 'description': 'Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .', 'interventionNames': ['Drug: Immucillin DI4G']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Meglumine Antimoniate', 'description': 'Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.', 'interventionNames': ['Drug: Meglumine antimoniate']}], 'interventions': [{'name': 'Immucillin DI4G', 'type': 'DRUG', 'otherNames': ['Fourth-generation Immucillin Derivative'], 'description': 'Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.', 'armGroupLabels': ['Immucillin DI4G']}, {'name': 'Meglumine antimoniate', 'type': 'DRUG', 'otherNames': ['Glucantime'], 'description': 'Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.', 'armGroupLabels': ['Meglumine Antimoniate']}]}, 'contactsLocationsModule': {'locations': [{'zip': '40000', 'city': 'Corte de Pedra', 'state': 'Estado de Bahia', 'country': 'Brazil', 'facility': 'Corte de Pedra Health Post', 'geoPoint': {'lat': -13.51116, 'lon': -39.45061}}], 'overallOfficials': [{'name': 'Edgar M Carvalho, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Federal University of Bahia'}, {'name': 'Paulo RL Machado, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Federal University of Bahia'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hospital Universitário Professor Edgard Santos', 'class': 'OTHER'}, 'collaborators': [{'name': 'Conselho Nacional de Desenvolvimento Científico e Tecnológico', 'class': 'OTHER_GOV'}, {'name': 'Federal University of Bahia', 'class': 'OTHER'}, {'name': 'Pontificia Universidade Católica do Rio Grande do Sul', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Fernanda V Prates, MD, MSc', 'investigatorAffiliation': 'Hospital Universitário Professor Edgard Santos'}}}}